Dohme announces FDA approval for grass pollen tablet

Merck Sharp & Dohme has announced the application for its investigational Timothy grass pollen allergy immunotherapy tablet has been accepted for review by the US Food and Drug Administration.

The company confirmed its request was supported by positive results from phase III clinical trials that tested the safety and efficacy of the product, including a long-term multi-season investigation.

Merck Sharp & Dohme's grass pollen immunotherapy tablet is an investigational sublingual dissolvable capsule that is designed to help individuals overcome the underlying cause of allergic rhinitis by generating an immune response to help against targeted allergens.

Jeffrey Chodakewitz, senior vice president of global scientific strategy and franchise head of infectious diseases at Merck Sharp & Dohme's research laboratories, said: "We are pleased to have achieved this important milestone in the development of our investigational grass pollen immunotherapy tablet, which, if approved, would represent a potential new option for allergy specialists to offer appropriate allergic rhinitis patient."